From Idea to Market: Ep 11 - Built to Last or Built to Sell?
Send us Fan Mail
Is your med tech company built to last, or built to sell? Voices from inside Stryker, XRSynergies, FIOS Health, and physician contract law explain why exit strategy is a design choice founders make on day one — whether they realize it or not.
In 2024, med tech M&A reached a record $474 billion in global transaction value. For most successful device startups, the path to broad patient reach runs through acquisition — and that reality shapes how experienced founders structure their companies from the moment of incorporation. Corporate form, consulting agreements, equity design…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.